The mTOR Targets 4E-BP1/2 Restrain Tumor Growth and Promote Hypoxia Tolerance in PTEN-driven Prostate Cancer

Mei Ding1, Theodorus H. Van der Kwast2, Ravi N. Vellanki1, Warren D. Foltz3,4, Trevor D. McKee1,3, Nahum Sonenberg5, Pier P. Pandolfi6, Marianne Koritzinsky1,4,7, and Bradly G. Wouters1,4,8,9

Abstract

The mTOR signaling pathway is a central regulator of protein synthesis and cellular metabolism in response to the availability of energy, nutrients, oxygen, and growth factors. mTOR activation leads to phosphorylation of multiple downstream targets including the eukaryotic initiation factor 4E (eIF4E) binding proteins-1 and -2 (eIF4EBP1/4E-BP1 and eIF4EBP2/4E-BP2). These binding proteins inhibit protein synthesis, but are inactivated by mTOR to stimulate cell growth and metabolism. However, the role of these proteins in the context of aberrant activation of mTOR, which occurs frequently in cancer through loss of PTEN or mutational activation of the PI3K/AKT pathway, is unclear. Here, even under conditions of PTEN or mutational activation of the PI3K/AKT pathway, is unclear. Here, even under conditions of...
protein synthesis during hypoxia is due to reduced phosphorylation of eukaryotic initiation factor 4E binding proteins (4E-BP), which bind to eIF4E in their under phosphorylated form and prevent its association with eIF4G at the 5’ cap (11, 12). In mammals, there are three members in 4E-BP family—4E-BP1, 4E-BP2, and 4E-BP3 (13). All three corresponding proteins are believed to negatively regulate eIF4E; however, only 4E-BP1 and 4E-BP2 have been shown to be regulated in a similar manner and expressed in most tissues, although 4E-BP2 is particularly high in brain (14). The ability of 4E-BP1 and 4E-BP2 to bind and inhibit eIF4E is prevented by mTOR-dependent phosphorylation on a number of sites (15). Consequently, mTOR inhibition during hypoxia leads to reduced phosphorylation of these proteins and consequential inhibition of eIF4E and cap-dependent translation (3).

The mTOR signaling pathway is a central regulator of cellular metabolism and is influenced by many upstream signaling pathways in response to the availability of nutrients and growth factors. mTOR signaling regulates cell growth and survival in response to PI3K/AKT signaling by controlling multiple anabolic processes including rates and capacity of protein synthesis and mitochondrial activity (16, 17). As such, it functions in part as a central coordinator of energy production and expenditure. Stimulation of protein synthesis occurs through mTOR increases in ribosome biogenesis, and direct phosphorylation of p70S6K (ribosomal protein S6 kinase), 4E-BPs and eEF2K (eukaryotic elongation factor 2), resulting in increased rates of initiation and elongation, and increased capacity of mRNA translation.

Aberrant activation of the PI3K/AKT/mTOR signaling pathway through loss of the tumor suppressor PTEN protein or mutations in proteins in the PI3K/AKT pathway are extremely common in prostate and other types of cancer. Because eIF4E levels are rate limiting, phosphorylation of 4E-BPs in response to PI3K/AKT signaling is a major regulator of cap-dependent translation. Consequential activation of mTOR signaling and increased activity of eIF4E cap-dependent translation is thought to be a critical mediator of its role in tumorigenesis. Indeed, it has shown in mouse models of prostate cancer that knock-in mice expressing a nonphosphorylatable form of eIF4E are resistant to tumorigenesis. Overexpression of eIF4E (eukaryotic initiation factor 4E) is found frequently in cancer, and has been shown to cooperate with other driver mutations like Kras to stimulate transformation (18–22). Similarly, aberrant activation of eIF4E through dual knockout of 4E-BP1 and 4E-BP2 has been shown to increase tumorigenesis in p53 knockout mice (23).

The importance and role of the 4E-BPs in the context of aberrant mTOR signaling and hypoxia in cancer has not been explored. Our previous data demonstrate that 4E-BPs play a critical role in mediating a stress response to hypoxia. We hypothesize that their ability to inhibit translation during conditions of extreme nutrient deprivation is critical to survival. We have shown that partial knockdown of 4E-BP1 resulted in loss of hypoxia tolerance and a reduction in the hypoxia observed in U87 glioblastoma xenografts in mice (24). Here, we have investigated the consequences of genetic loss of 4E-BP1 and 4E-BP2 in the context of PTEN-driven models of prostate cancer. Our data reveal that through loss of these regulators, mRNA translation accelerates tumorigenesis even in the context of PTEN loss, and the tumors that arise show substantial reductions in their ability to tolerate hypoxia.

### Materials and Methods

#### Generation of transgenic mice

All animal experimentation was conducted in accordance with the Canadian Guide for the Care and Use of Laboratory Animals, and protocols were approved by the Animal Care Committee at the Princess Margaret Hospital Cancer Center, University Health Network, University of Toronto (Toronto, Ontario, Canada). The Probasin-Cre mouse line expresses Cre-recombinase transcript under control of mouse prostate epithelial-specific probasin promoter. The Pten<sup>fl/fl</sup> mice and Probasin-Cre mice were kindly provided by Dr. Pier P. Pandolfi’s laboratory (25). Mouse lines with 4E-BP1 and 4E-BP2 knockout were kindly provided by N. Sonenberg’s laboratory (26). To generate mice with prostate epithelial-specific Pten gene deletion, Pten<sup>fl/fl</sup> mice were bred to probasin-Cre mice. To generate mice carrying Pten deletion in 4E-BP1 and 4E-BP2 knockout background, Pten<sup>fl/fl</sup>/Probasin-Cre mice were bred to 4E-BP1- and 4E-BP2-knockout and Pten<sup>fl/fl</sup> mice. After several breedings, mice carrying all four transgens (Pten<sup>fl/fl</sup>, probasin-Cre, 4E-BP1, and 4E-BP2 knockout) were obtained. Genotypes were confirmed by PCR.

The genetic background strain for Pten<sup>fl/fl</sup> mice and 4E-BP1/2 knockout is C57/Black 6, and for Probasin-Cre mice is mixed. Littermates were used for all comparisons and analyses.

#### Genotype analysis

Genomic DNA from tails of 3 weeks of age transgenic mice was isolated and used for genotypic PCR analysis as described previously (25, 26).

#### Histologic and pathologic analysis

Transgenic mouse prostates were dissected, fixed in 10% formalin in PBS, and embedded in paraffin. Sections (4-μm thick) were cut and stained with hematoxylin and eosin (H&E), examined, and photographed with a Leica camera DFC 320 and Leica DMLB microscope (Leica Microsystems).

#### EF5 administration

To identify hypoxia regions of the prostate tumor, mice received an injection of the hypoxia marker drug EF5 [2-(2-nitro-1H-imidazole-1-yl)-N-(2,2,3,3-pentamfluoropropyl)acetamide], 3 hours before tumor excision (27). To achieve optimal drug distribution and tumor staining, each mouse received a total body dose of 10 μg i.p. of a 10 mmol/L EF5 in 2.4% EtOH, 5% dextrose.

#### Immunostaining analysis (IHC)

Prostate tissue was fixed in 10% formalin and embedded in paraffin, and 4-μm thick sections were prepared. Primary antibodies used were: phospho-4E-BP1 1:50 dilutions (Cell Signaling Technology), 4E-BP2 1:100 dilutions (Cell Signaling Technology), phospho-eIF4E 1:500 dilutions (BD Biosciences). IHC for detection of tumor vasculature was achieved by staining CD31 antibody, 1:500 dilution (Santa Cruz Biotechnology), respectively. Apoptosis was assessed using caspase-3 antibody, 1:200 dilution (Cell Signaling Technology) and hypoxia was assessed using an EF5 antibody, 1:150 dilution (provided by Dr. Cameron Koch, University of Pennsylvania, Philadelphia, PA) in caspase-3 and EF5 double immunostaining. Images with EF5 staining (red), caspase-3 (green), and DAPI counterstain (blue) were obtained from immunofluorescence-stained slides.
digitized at 1-µm/pixel resolution on a Huron Technologies TissueScope scanner. Image analysis was performed on Definiens TissueStudio software, in which 5–7 representative regions were segmented to separate prostate tumor from lumen, and prostate tumor regions were quantified to identify the number of positively stained EF5 cells, caspase-3 cells and EF5/caspase coexpressed cells as a percentage of the total cells in the tumor region.

MRI analysis
MR images to visualize morphologic changes in the murine genitourinary region over time were acquired using a 7 Tesla preclinical MRI system (BioSpec 70/30, Bruker Corporation), equipped with a B-GA12 gradient coil insert. 7.2-cm inner diameter linearly polarized RF volume coil, and 4-coil phased-array surface receiver coil. Mice were anesthetized and maintained at 1.8% isoflurane delivered via nose cone, and respiration was monitored using a pneumatic pillow (SA Instruments). Imaging was then performed with mice oriented in prone position above the posteriorly placed phased-array coil. The prostate gland and genitourinary region was resolved using a stack of 2D T2-weighted Rapid Acquisition with Refocused Echoes (RARE) images with echo time 48 ms, repetition time 4,200 ms, and spatial resolution of at least 0.13 × 0.13 × 1 mm. Slice thickness increased from 0.5 to 1 mm during the course of the study to encompass the enlarging prostate volume, and scan times were then correspondingly reduced from 15 to 8 minutes given higher signal-to-noise in thicker slice acquisitions.

Cell cultures
HCT116, DU145, PC3, and LNCAP cell lines were obtained from ATCC. Cell line authenticity was confirmed by short tandem repeat (STR) profiling every 2 months and cell lines were also checked for mycoplasma contamination at the same frequency. All cell lines were grown in RPMI supplemented with 10% FBS. Viral particles from pLKO.1 shRNA knockdown vectors were produced as described previously (28). 4E-BP1 shRNA target sequence is GCCAGGCCCTTATGAAAGTGAT. 4E-BP2 shRNA target sequence is CTCGAATCATTTATGACAGAA. For hypoxic exposure, cells were seeded 24 hours prior to transfer to a hypoxia culture chamber (MACS VA 500 microaerophilic workstation, Don Whitley Scientific).

Western blotting
Primary antibodies were used at the following dilutions: 4E-BP1 1:1,000 (Cell Signaling Technology), 4E-BP2 1:1,000 (Cell Signaling Technology), phosphor 4E-BP1 T37/46 1:1,000 (Cell Signaling Technology), phosphor 4E-BP2 S65 1:1,000 (Cell Signaling Technology). ef4E 1:1,000 (BD Biosciences), β-actin 1:10,000 (MP Biomedicals). HRP-secondary rabbit antibody was used at 1:5,000 dilutions (GE Healthcare). Experiments were performed a minimum of three times.

Immunoprecipitation
Cells were lysed and protein was extracted with lysis buffer (5 mM/L HEPES-KOH pH 7.5, 150 mM/L KCl, 1 mM/L EDTA pH 8.0, 2 mM/L DTT, 0.2% Tween-20). Four-hundred micrograms of extracted protein was incubated with 50 µL of 7-methyl-GTP sepharose resin (GE Healthcare) overnight at 4°C. The resin was washed, boiled in Laemmli buffer, and the polypeptides in the supernatant were resolved on a large gradient SDS-PAGE, transferred to nitrocellulose membrane and immunoblotted. All experiments were performed in triplicate.

Clonogenic assay
Colony formation assays were performed in triplicate on the relevant cell lines in parallel, with appropriate controls following hypoxia (0.2%) exposure in 60-mm petri dishes as described previously (29).

Statistical analysis
Student t test (two-sided) was calculated using GraphPad Prism (GraphPad software, Inc.) to test for statistical differences. P values <0.05 were considered significant. The log-rank test was used to compare for statistically significant differences in cancer-free survival (Kaplan–Meier survival curve) and was performed using R version 3.0.1. A one-way ANOVA and Tukey method was calculated for Ki67 and CD31 immunostaining quantification. Mann–Whitney test and t test were used to evaluate the significance in comparison of different groups in EF5, caspase-3 immunostaining quantification.

Results
4E-BP1 and 4E-BP2 are dephosphorylated during hypoxia and inhibit eIF4F formation in human prostate cells
To evaluate the functional roles of 4E-BP1 and 4E-BP2 in hypoxia, we analyzed 4E-BP1 and 4E-BP2 levels during normoxia and hypoxia conditions at different time points in three human prostate cell lines with different genetic background—DU145, PC3, and LNCAP (Fig. 1A–C). DU145 and PC3 cells have both been reported to have loss of PTEN function and consequently mTOR activation. As shown previously, 4E-BP1 migrates as three different bands representing different phosphorylation levels with the fastest migrating band representing the dephosphorylated version (30). In DU145 cells (Fig. 1A), 4E-BP1 was substantially dephosphorylated during exposure to 0.2% O2 at 24, 48, and 72 hours and exposure to 0% for 24 hours as evidenced by a loss of the slowest migrating band and a concomitant increase in the two higher mobility bands. Phosphorylation-specific 4E-BP1 antibodies for T37/46 and S65 confirmed the 4E-BP1 dephosphorylation during 24- to 72-hour exposure to 0.2% O2. 4E-BP2 expression was weak at 72-hour exposure to 0.2% O2 (Fig. 1A). In PC3 cells, 4E-BP1 was also dephosphorylated during exposure to 0.2% O2 24- to 72 hours; however, there was no change in phosphorylation of 4E-BP1 S65 antibody and only mild dephosphorylation displayed during 72-hour exposure to 0.2% O2 and 24-hour exposure to 0% O2. There were no significant differences in 4E-BP2 expression during normoxia or hypoxia at different time points (Fig. 1B). In LNCAP cells, we saw similar evidence of 4E-BP1 dephosphorylation only after 0.2% O2 for 72 hours or 0% O2 for 24 hours (Fig. 1C). No change was observed at 24 or 48 hours of 0.2% O2.

The assembly of the eIF4F complex for mRNA cap-dependent translation is the critical determinant of translation initiation. 4E-BPs compete with eIF4G for a common binding site to eIF4E and it is mutually exclusive. As 4E-BP dephosphorylation during hypoxia can increase binding to eIF4E, this can lead to eIF4E separation from eIF4G and disrupt eIF4F formation and cap-dependent translation. To further test the functional effects on 4E-BP dephosphorylation in DU145 and PC3 prostate cell lines during exposure to 0.2% O2, immunoprecipitation (IP) methods
using m7GTP Sepharose resin to pull down eIF4E protein were performed and assessed in a large gradient gel to detect the expression of eIF4G (200 kDa), eIF4E (25 kDa), and 4E-BP1 or 4E-BP2 (15–20 kDa) using Western blotting (Fig. 1D and E). During 21% normoxia conditions, eIF4E is associated with eIF4G, consistent with formation of an active eIF4F complex and efficient translation initiation (11). In DU145 cells, which had low levels of eIF4G bound to eIF4E, there was a dramatic decrease in the binding of eIF4G to eIF4E and a strong increase in the association of 4E-BP1 and 4E-BP2 with eIF4E during exposure to 0.2% O2 at 24, 48, and 72 hours (Fig. 1D, lane 2–4) compared with 21% O2 condition (Fig. 1D, lane 1). In PC3 cells (Fig. 1E), there was a large
amount of eIF4G binding to eIF4E during exposure to 21% O₂ and also at 0.2% O₂ for 24 to 72 hours, with only slightly increased levels of 4E-BP1 associated with eIF4E during 0.2% O₂ conditions. We also found a substantial increase in 4E-BP2 association with eIF4E during hypoxia. Thus, despite the increased binding of 4E-BP1 and 4E-BP2 to eIF4E, there was only a modest effect on eIF4E association with eIF4G in PC3 cells, which was expressed at high levels in this cell line. Interestingly, we also observed a decrease in overall levels of eIF4G after longer times of hypoxia exposure (after 48 hours in DU145 and after 72 hours in PC3), which may exacerbate the effect of hypoxia on inhibition of the eIF4F complex. However, our data demonstrate that 4E-BP dephosphorylation during hypoxia strongly inhibits eIF4G binding to eIF4E within 24 hours in DU145 cells.

To understand the relative role of 4E-BP1 and 4E-BP2 in inhibiting eIF4F formation and mRNA cap-dependent translation initiation during hypoxia exposure in DU145 cells, we used lentivirus to infect and express two distinct shRNAs to knockdown initiation during hypoxia exposure in DU145 cells, we used inhibiting eIF4F formation and mRNA cap-dependent translation eIF4G binding to eIF4E within 24 hours in DU145 cells. However, our data demonstrate that 4E-BP dephosphorylation during hypoxia strongly inhibits eIF4F formation and cap-dependent mRNA translation during hypoxia. To assess the functional consequences of 4E-BP dephosphorylation during hypoxia, cap pulldowns were performed at different time points (Fig. 2B). As expected, there were no changes in eIF4E expression. A large amount of eIF4G association and low levels of eIF4F were observed at 21% O₂ normoxia (Fig. 2B, lanes 1 and 2). In contrast, after 72-hour exposure to 0.2% hypoxia and 0% O₂ conditions, there was loss of eIF4G association and increases in both 4E-BP1 and 4E-BP2 (Fig. 2B, lanes 3 and 4). To further confirm the role of 4E-BP1 and 4E-BP2 individually, we knocked down each as described above for DU145 (Fig. 2C). During 21% O₂ conditions, there was no difference in eIF4G expression in 4E-BP1 knockdown, 4E-BP2 knockdown, and control shGFP cells. As seen earlier with DU145 cells, eIF4G association with eIF4E was partially restored during 72-hour exposure to 0.2% O₂ in each of the 4E-BP1 or 4E-BP2 knockdown cells (Fig. 2D, lanes 5 and 6) compared with a nontargeting control shGFP cell line (Fig. 2D, lane 4). Thus, in both DU145 prostate cancer and HCT116 colon cancer cells, both 4E-BP1 and 4E-BP2 contribute to inhibition of eIF4E and cap-dependent mRNA translation during hypoxia.

4E-BP1 and 4E-BP2 dephosphorylation during hypoxia is required to inhibit eIF4F formation in HCT116 colon cancer cells

To further examine the role of 4E-BP1 and 4E-BP2, we conducted similar experiments in HCT116 colon cancer cells, which have aberrant mTOR activation resulting from an activating mutation in PIK3CA (31). The levels of 4E-BP1, 4E-BP2, and phosphorylated 4E-BP1 (S65 and T37/46) were measured during hypoxia. Figure 2A demonstrates that like DU145 prostate cancer cells, 4E-BP1 was dephosphorylated after 24-hour exposure in 0.2% O₂ conditions, and maintained at 48 and 72 hours after 0.2% O₂ exposure. 4E-BP2 was noticeably dephosphorylated only at 72 hours in 0.2% O₂. Furthermore, there was no detectable S65 phosphorylation after 24-, 48-, and 72-hour exposure in 0.2% O₂. However, knockdown of either 4E-BP1 or 4E-BP2 was sufficient to partially restore eIF4G binding to eIF4E during 72-hour exposure to 0.2% O₂ in each of the 4E-BP1 or 4E-BP2 knockdown cells (Fig. 2D, lanes 5 and 6). As expected, there were no changes in eIF4E expression. A large amount of eIF4G association and low levels of eIF4F were observed at 21% O₂ normoxia (Fig. 2B, lanes 1 and 2). In contrast, after 72-hour exposure to 0.2% hypoxia and 0% O₂ conditions, there was loss of eIF4G association and increases in both 4E-BP1 and 4E-BP2 (Fig. 2B, lanes 3 and 4). To further confirm the role of 4E-BP1 and 4E-BP2 individually, we knocked down each as described above for DU145 (Fig. 2C). During 21% O₂ conditions, there was no difference in eIF4G expression in 4E-BP1 knockdown, 4E-BP2 knockdown, and control shGFP cells. As seen earlier with DU145 cells, eIF4G association with eIF4E was partially restored during 72-hour exposure to 0.2% O₂ in each of the 4E-BP1 or 4E-BP2 knockdown cells (Fig. 2D, lanes 5 and 6). Thus, in both DU145 prostate cancer and HCT116 colon cancer cells, both 4E-BP1 and 4E-BP2 contribute to inhibition of eIF4E and cap-dependent mRNA translation during hypoxia.
4E-BP1 or 4E-BP2 knockdown reduces hypoxia tolerance in HCT116 and DU145 cells

To determine the phenotypic properties of 4E-BP1 and 4E-BP2 on tumor hypoxia tolerance, we created stable knockdown of 4E-BP1 and 4E-BP2 using lentiviruses expressing shRNAs against both of these individually or in combination (Fig. 3A) and assessed the overall toxicity of hypoxia exposure of differing periods using the clonogenic assay. In Fig. 3B, DU145 prostate cancer cells with knockdown of either 4E-BP1 or 4E-BP2 knockdown demonstrated substantial reduced surviving fractions in 0.2% hypoxia at all time points evaluated. The reduction in hypoxia tolerance was more severe following knockdown of 4E-BP1 than with knockdown of 4E-BP2 knockdown, perhaps due to higher expression of 4E-BP1. However, the data clearly

Figure 3.

4E-BP1 or 4E-BP2 knockdown reduces hypoxia tolerance. A, Western blot analysis for 4E-BP1, 4E-BP2, and γ-tubulin in DU145 cells following knockdown with the indicated shRNA lentiviruses. B and C, Clonogenic assays evaluating the toxicity of hypoxia (0.2% O₂) for the indicated periods of time for DU145 prostate cancer (B) and HCT116 colon cancer (C) cells following knockdown with the indicated lentiviruses.
Loss of 4E-BP1 and 4E-BP2 gene function in a prostate cancer mouse model with Pten deficiency increases tumorigenesis

To investigate the functional role of 4E-BP1 and 4E-BP2 in prostate cancer development and tumor hypoxia in vivo, we crossed 4E-BP1 and 4E-BP2 knockout mice into a well-established prostate cancer mouse model driven by conditional Pten gene deletion. In this model, Pten is specifically lost in prostate epithelial cells by crossing mice with homozygous floxed Pten alleles (Pten<sup>lox/lox</sup>) to the prostate epithelial promoter - Probasin-Cre mice (Fig. 3C). In this line, the survival of 4E-BP1 knockdown lines was also lower than 4E-BP2 knockdown. These data indicate that in both of the mTOR-deregulated cell lines examined, 4E-BP1 and 4E-BP2 are able to be dephosphorylated during hypoxia, and are required to prevent eIF4F formation and to preserve hypoxia tolerance during hypoxia.

Loss of 4E-BP1 and 4E-BP2 gene function in a prostate cancer mouse model driven by conditional Pten gene deletion. In this model, Pten is specifically lost in prostate epithelial cells by crossing mice with homozygous floxed Pten alleles (Pten<sup>lox/lox</sup>) to the prostate epithelial promoter - Probasin-Cre mice (Fig. 3C). In this line, the survival of 4E-BP1 knockdown lines was also lower than 4E-BP2 knockdown. These data indicate that in both of the mTOR-deregulated cell lines examined, 4E-BP1 and 4E-BP2 are able to be dephosphorylated during hypoxia, and are required to prevent eIF4F formation and to preserve hypoxia tolerance during hypoxia.

Loss of 4E-BP1 and 4E-BP2 gene function in a prostate cancer mouse model driven by conditional Pten gene deletion. In this model, Pten is specifically lost in prostate epithelial cells by crossing mice with homozygous floxed Pten alleles (Pten<sup>lox/lox</sup>) to the prostate epithelial promoter - Probasin-Cre mice (Fig. 3C). In this line, the survival of 4E-BP1 knockdown lines was also lower than 4E-BP2 knockdown. These data indicate that in both of the mTOR-deregulated cell lines examined, 4E-BP1 and 4E-BP2 are able to be dephosphorylated during hypoxia, and are required to prevent eIF4F formation and to preserve hypoxia tolerance during hypoxia.

**Figure 4.** Loss of 4E-BP1 and 4E-BP2 increase tumorigenesis in a prostate cancer mouse model. A, Breeding strategy and analysis of cancer development in four genotypes. Pten<sup>lox/lox</sup>Probasin-Cre mice were bred to mice with 4E-BP1/2 double knockout mice: Cre-mediated excision leads to loss of Pten gene in prostate epithelium in 4E-BP1/2 knockout background. B, Four groups of mice were separated according to genotyping results as indicated. Cohorts of each group of mice were analyzed at 2–6 months, 8–10 months, 12–13 months, 14–15 months, 16–17 months. All mice in Group A died before 14 months of age. The number of mice in each group analyzed at different time points are indicated in brackets. C, MRI imaging: representative T2-weighted images of the murine prostate gland and surrounding region, from each cohort and time-point, demonstrating group differences in enlargement of the prostate gland volume over time. D, The weight of prostates in each group at different time points was measured. E, Kaplan-Meier survival curve shows that mice in Group B with Pten KO survive approximately 4 months longer than mice in Group A with Pten KO + 4E-BP1/2 KO background. Survival curves were compared using the log-rank test.
analyzed at 2–6 months (Group A n = 14, Group B n = 12, Group C n = 18, Group D n = 19), 8–10 months (Group An = 9, Group B n = 10, Group C n = 8, Group D n = 6), 12–13 months (Group A n = 5, Group B n = 6, Group C n = 5, Group D n = 4), 14–15 months (Group B n = 3, Group C n = 3, Group D n = 3), and 16–17 months of age (Group B n = 5, Group C n = 6, Group D n = 3; Fig. 4A). We found that all cohorts of mice in Group A developed aggressive disease and died before 14 months of age; however, mice in Group B survived until 17–18 months of age. Mice in Group C and Group D have the same life span as normal mice (Fig. 4A).

We monitored prostate cancer development and other morphologic changes over time using MRI. We observed morphologic changes in the prostate gland in these four groups of mice between 5 months and 12 months of age (Fig. 4B). Obvious differences in glandular shapes and volumes were observed in Group A compared with Group B after 6–7 months, presenting as balloon-like structures of high T2-weighted MRI signal intensity which were noted as filled with secretory fluids and enlarged glandular components upon dissection (data not shown). After 11–12 months of age, the prostate glands of mice in Group A were very large compared with other groups of mice.

Second, cohorts of mice in these four different groups were sacrificed at different times ranging from 2 months to 17 months of age bimonthly. The weight of the prostate was measured after dissection (Fig. 4C). After 6 months of age, the weight of the mice prostate in Group A increase significantly over the other groups; and the mice prostate in Group B also increase, but much less than mice in Group A (Fig. 4C). Histologic and pathologic analysis showed that mice of 6–7 months of age in Group A with Pten KO only develop glandular hyperplasia in the prostate compared with normal control Groups C and D (Supplementary Fig. S2A). Around 8–10 months of age (Fig. 5A; Supplementary Fig. S2B), 9 of 9 mice in Group A demonstrated massive hyperplasia within the prostatic gland with nuclear features consistent with PIN to high-grade PIN (prostate intraepithelial neoplasia). Compared with Group A, 10 of 10 mice in Group B demonstrated a much more moderate level of glandular hyperplasia and similarly more moderate nuclear features. At 12–13 months of age (Fig. 5B), 4 of 5 mice in Group A demonstrated intense glandular hyperplasia invading stroma, features consistent with invasive prostate adenocarcinoma. However, 6 of 6 mice in Group B at the same time showed only contained intraglandular hyperplasia and nuclear features consistent with PIN. Mice in Group A did not survive longer than 14 months of age. In contrast, mice in Group B progressed towards adenocarcinoma at a much slower rate (Fig. 4E). At 14 months of age, 3 of 3 mice in Group B showed initial features of more intense prostate glandular proliferation and nuclear atypia consistent with PIN (Supplementary Fig. S2C). Around 16–17 months of age (Fig. 5C), 3 of 5 mice in Group B were found to have developed an invasive phenotype consistent with adenocarcinoma, which is similar to that reported for this model by other research groups (25). Mice in control Group C with 4E-BP1/2 KO from 10 months of age to 17 months of age were found to have minor abnormal features including slightly enlarged nuclei and occasionally with one or a few conspicuous nucleoli as compared with the wild-type prostate glands in Group D. These results suggest that loss of 4E-BP1/2 gene function in Pten-deficient mouse model accelerates prostate tumorigenesis.

Immunostaining tests for 4E-BP1 and 4E-BP2 confirmed the deletion of 4E-BP1 and 4E-BP2 protein in the mice of Group A (Fig. 5D and E). Similarly, a phosphorylation-specific AKT antibody confirmed AKT activation in Group A and B only with high immunostaining signals around the plasma membrane as expected.

Loss of 4E-BP1 and 4E-BP2 gene function in Pten-deficient prostate mouse model increases vascular density and reduces hypoxia tolerance

Previous results have demonstrated that importance of eIF4E phosphorylation in driving tumorigenesis in a similar prostate cancer mouse model (32). We therefore evaluated if eIF4E phosphorylation differed in mice with Pten deficiency versus those with both Pten and 4E-BP1 and 4E-BP2 deficiency. Immunostaining for eIF4E phosphorylation in Group A and Group B at 10 and at 12 months of age showed substantially increased phosphorylation in the prostate epithelium relative to wild-type mice, but no differences between those with or without the 4E-BPs (Supplementary Fig. S3). Consequently, eIF4E phosphorylation cannot account for the differences between cancer development in these groups. eIF4E activation has also been shown to drive proliferation and we hypothesized that the differences in cancer development between Groups A and B may be due to differential proliferation. However, there was no significant difference in Ki67 immunostaining between mice of Groups A and B measured at 8 or 12 months and also no correlation between proliferation and stage of prostate cancer development (Fig. 6A and B). These data indicate that loss of Pten is sufficient to drive the prostate epithelial cells into a constitutive proliferative mode, and that this is not further augmented by 4E-BP1 and 4E-BP2 loss or other events in prostate cancer progression.

We also probed differences in vascularity of the prostate lesions over time at 8, 12, and 16 months. At 8 and 12 months, significantly higher CD31 immunostaining signals were observed in mice of Group A, demonstrating that increased vascular density in Group A compared with Group B (Fig. 6C and D) at equivalent points of time. This acceleration of vascularity was consistent with the more rapid progression of the Pten-deficient 4E-BP1 and 4E-BP2 knockout mice. Vascularity also increased to similar levels in the 4E-BP proficient mice, but at later time points where prostate lesions progressed. However, even at 16 months, the overall vascularity in the 4E-BP1 and 4E-BP2–proficient tumors was reduced compared with the knockout tumors suggesting that this pathway may play a key role in driving angiogenesis.

Finally, given the important role of mTOR suppression and 4E-BP phosphorylation in suppressing protein synthesis during hypoxia, we also assessed differences in hypoxia and hypoxia tolerance in these models. We hypothesized that in the presence of aberrant mTOR, 4E-BP1, and 4E-BP2 would still be required during hypoxia to suppress eIF4F formation and promote hypoxia tolerance. To test this hypothesis, we measured viable areas of tumor hypoxia using hypoxia marker EF5 in mice from Groups A and B at 10, 12, and 16 months of age. We found that EF5 staining of viable hypoxic cells was very strong in mice of Group A at 10 months when they had developed high-grade PIN, but was reduced significantly at 12 months when invasive cancer had been established (Fig. 6E). The quantification of EF5 immunostaining also showed that the differences between 10 months and 12 months old of mice in Group A were significant (Fig. 6F). In contrast, in mice of Group B, there was less red EF5 immunostaining signals at 10 months and 12 months (low-grade PIN stage) consistent with the slow progression in this model, but that
Group A: Pten-/-BP1-/-BP2-/

Group B: Pten-/-

Group C: BP1-/-BP2-/

Group D: Wild-type

8 Months 12 Months

10p 20p 40p

16 Months

10p 20p 40p

8 Months 12 Months

10p 20p 40p

10 Months 12 Months

Ding et al. Mol Cancer Res; 16(4) April 2018 Molecular Cancer Research
hypoxia increased substantially at the time when these mice had developed invasive cancer at 16 months of age (Fig. E and F). These data imply that at the stages where prostate cancer had developed (10 months: for Group A and 16 months for Group B), the tumors lacking 4E-BP1 and 4E-BP2 have significantly less hypoxia. Although it is difficult to set a threshold on where true malignancy occurs in each model, these data indicate that as malignancy evolves in the tumors lacking 4E-BP1 and 4E-BP2 they show decreased levels of hypoxia, consistent with an inability to support hypoxic cell survival. The 4E-BP wild-type mice show the opposite with increased levels of hypoxia in the mature tumors.

To understand whether the decreasing hypoxia observed during tumor development in mice of Group A was due to loss of hypoxia tolerance, we performed the EF5/Caspase-3 double immunostaining on tumor samples. The results demonstrate significantly higher caspase-3 signals within hypoxia regions (green + red) in Group A 4E-BP1 and 4E-BP2 knockout mice compared with Group B at 10 months and at 12 months of age (Fig. 6G and H). At 12 months of age, caspase-3 activation was significantly reduced in hypoxic regions in mice of Group A. In mice of Group B, there were several weak caspase-3 signals in hypoxia at 10 months and 12 months of age (Fig. 6G and H). The caspase-3 signals became stronger in red EF5 hypoxia region in mice of Group B at 16 months of age, when the prostate cancer has been fully developed. These data show that hypoxic cells do not survive in mice of Group A during tumor development, and that expression of 4E-BP1 and 4E-BP2 in the presence of Pten deficiency may be critical for cancer cells to survive hypoxia in the presence of aberrant mTOR activation.

Discussion

Our study reveals two key aspects on the role of the mTOR targets 4E-BP1 and 4E-BP2 in the development and aggressiveness of prostate cancer. First, we found that loss of these negative regulators of mTOR signaling accelerated prostate cancer development in a mouse model driven by Pten deficiency in the prostate. Thus, even in the case of deregulated PI3K signaling and constitutive mTOR activation, 4E-BP1 and 4E-BP2 constrained signaling downstream of mTOR. Interestingly, this effect appears to be unrelated to effects on cell proliferation. We found no difference in eIF4E phosphorylation, PI3K activation, or proliferation as assessed by Ki67 or EdU incorporation (data not shown) between prostate cancer mice with knockout of 4E-BP1/2 and wild-type. However, we did find that accelerated tumorigenesis was associated with a significant increase in angiogenesis and vascular development as assessed by increased in CD31 immunostaining. These results are similar to observations reported in a carcinogen-induced lung cancer model in 4E-BP1/2 KO mice (33). These mice also showed accelerated tumorigenesis (albeit in the absence of a defined upstream activator of mTOR) without significant changes in proliferation between the WT 4E-BP1/2 KO mice. In addition, the lung cancers arising in the 4E-BP1/2 KO mice demonstrated elevated microvessel density by CD31 immunostaining.

Second, our study demonstrates that although loss of 4E-BP1 and 4E-BP2 accelerates prostate cancer development, the tumors that develop have reduced levels of hypoxic cells. Hypoxic levels dropped substantially during the development of PTEN loss-driven prostate cancer in the 4E-BP1/2 KO mice, whereas they increased as cancer developed in the WT mice. Hypoxia is a known negative prognostic indicator in prostate cancer, associated with treatment resistance, increased metastasis, and increased genomic instability. Consequently, although these tumors develop more rapidly, they are associated with a subtype of prostate cancer that in humans has a better prognosis due to less hypoxia. Increased microvessel density in the 4E-BP1/2 KO tumors may contribute to the reduced levels of hypoxia in these tumors, although high CD31 levels were observed throughout progression from PIN to cancer, whereas hypoxic levels dropped only once cancers had developed. Our data indicate that 4E-BP1/2 are important during hypoxia to promote cell survival in cells with aberrant mTOR activation. Hypoxia suppresses mTOR signaling to inhibit translation and conserve energy, and in vitro we found that loss of 4E-BP1 and 4E-BP2 compromised the ability of hypoxic cells to survive hypoxic stress. We examined changes in
Figure 6.
Loss of 4E-BP1/2 gene expressions in prostate cancer model with Pten gene deficiency leads to increased vascular density and reduce hypoxia tolerance.
A, Ki 67 immunostaining demonstrated that increased proliferative activity of prostate epithelial cells both in Groups A and B compared with control Groups C and D at 8 months, 12 months, and 16 months of age. Original magnification, 2,000 x. B, Ki 67 immunostaining quantification. No significant difference between mice in Groups A and B, but Ki-67 labeling was higher in both Groups A and B than control Groups C and D at 8 months, 12 months, and 16 months of age. C, CD31 immunostaining demonstrated increased vascular density in Group A compared with Group B and control group at 8 months, 12 months, and 16 months of age. Original magnification, 1,000 x. (Continued on the following page.)
4E-BP1/2 phosphorylation and function during hypoxia in PC3, LNCAP, and DU145 prostate cancer cell lines. In the DU145 cell line, we showed that 4E-BPs were dephosphorylated rapidly during mild hypoxia (0.2% O₂), inhibited eIF4E binding to eIF4G, and were required to promote cell survival. Milder effects were observed on 4E-BP phosphorylation in PC3 cells but with similar kinetics, whereas LNCAP cells showed no changes in phosphorylation until 72 hours of 0.2% O₂. Interestingly, DU145 and PC3 cells have a reported loss-of-function mutation in PTEN, whereas LNCAP does not (Cancer Cell Line Encyclopedia). However, we observed a similar effect on 4E-BP phosphorylation and requirement for 4E-BP to promote hypoxia tolerance in the colon cancer cell line HCT116, which harbors a PIK3CA mutation and consequently elevated mTOR signaling. Thus, our data suggest that PTEN loss–driven cancers need to maintain some ability to suppress signaling downstream of mTOR to promote survival during times of oxygen limitation.

In this study, our data indicate that both 4E-BP1 and 4E-BP2 are involved and important factors in preventing eIF4F formation and cap-dependent mRNA translation during hypoxia. This suggests that 4E-BP1 and 4E-BP2 have similar and partially redundant functions in regulating eIF4E during hypoxia. Although both 4E-BP1 and 4E-BP2 knockdown can reduce hypoxia tolerance in HCT116 and DU145 cell lines, 4E-BP1 appeared to provide a higher level of tolerance to hypoxia. The 4E-BP family has three proteins in mammals—4E-BP1, 4E-BP2, and 4E-BP3. Although 4E-BP1 and 4E-BP2 have been shown to be regulated in a similar manner, the role of 4E-BP2 is reported to be weaker than that of 4E-BP1 in response to ischemia/reperfusion stress (13) and insulin treatment (14), which may be related to the relative expression of these two different proteins. Consistent with our findings, 4E-BP1 is also reported as the major factor regulating cap-dependent translation by AKT and MEK signaling in HCT116 cells (34). 4E-BP3 shares the basic structural and functional features of 4E-BP1 and 4E-BP2, but its regulation is unique and different (35). Phosphorylation sites that are critical for regulation of 4E-BP1 and 4E-BP2 by mTOR (36) are absent from 4E-BP3. 4E-BP3 has been reported to bind to nuclear eIF4E and inhibit eIF4E-mediated mRNA export (37). Our studies do not address a

Figure 7.
Principle of mTOR signaling in tumor normoxia and hypoxia. In cancer heterogeneity, the function of mTOR signaling is different between tumor normoxia and hypoxia. In normoxia conditions, mTOR signaling is activated, and phosphorylated downstream factors 4E-BPs release eIF4E, which combine eIF4G and other factors such as eIF4A and eIF4B to initiate mRNA cap-dependent translation. In contrast, in hypoxia conditions, mTOR signaling is inhibited and dephosphorylated 4E-BPs bind to eIF4E, which cannot combine eIF4G to initiate mRNA cap-dependent translation.
potential residual function for 4E-BP3 in suppressing translation and contributing to hypoxia tolerance.

In summary, in this study we have demonstrated key roles for 4E-BP1 and 4E-BP2 during tumor development and during tumor hypoxia. We find that these factors maintain an ability to slow tumor progression in prostate cancer in the face of constitutive mTOR activation arising from loss of PTEN, and are also important in promoting survival of hypoxic cells once cancer has developed (Fig. 7). These findings have implications for use of mTOR inhibitors alone or in combination in cancer which function in a manner analogous to loss of 4E-BP1/2. Although such inhibitors may slow proliferation associated with activated mTOR gene regulation, they may also promote the survival of hypoxic cells that are resistant to other forms of therapy. Conversely, our in vitro data and new mouse model suggest that targeting 4E-BPs may be a novel way to selectively target and kill hypoxic cells in PTEN-deficient or mTOR-activated tumors.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors’ Contributions

Conception and design: M. Koritzinsky, B.G. Wouters
Development of methodology: M. Ding, R. Vellanki, W. Foltz, T. McKee, B.G. Wouters

References

34. She QB, Hallilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010;18:39–51.